HCM - HUTCHMED Highlights Clinical Data to be Presented at 2023 ESMO Asia and ESMO Immuno-Oncology Congresses | Benzinga
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Nov. 30, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:?HCM; HKEX:?13) today highlights that new clinical data from several ongoing studies with HUTCHMED investigational drug candidates fruquintinib, surufatinib and HMPL-295, which will be presented at the upcoming European Society for Medical Oncology ("ESMO") Asia Congress, taking place on December 1-3, 2023 in Singapore, and the ESMO Immuno-Oncology Congress, taking place on December 6-8, 2023 in Geneva, Switzerland.
HMPL-295:
| Title: |
| A first in human, open-label, dose-escalation study of ERK1/2 inhibitor HMPL-295 in patients with advanced solid tumors |
| Lead Author: |
| Rujiao Liu, Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China |
| Type: |
| Oral presentation |
| Abstract # & Link: |
| 77MO |
| Session & Location: |
| ESMO Asia – Developmental and precision medicine (ID 29), Hall 402 |
| Date & Time: |
| Friday, December 1, 2023, 11:50 am Singapore time |
This presentation will report data from a multi-center, open-label clinical trial to evaluate safety, tolerability, pharmacokinetics and preliminary efficacy profile of HMPL-295, and to determine the maximum tolerated dose ("MTD") and recommended Phase II dose in patients with advanced malignant solid tumors. The continuous-administration MTD was determined to be 50 mg QD, and intermittent administration studies are ongoing.
HMPL-295 is an investigational, selective, oral inhibitor of extracellular signal-regulated kinase 1 & 2 (ERK1/2), which is a downstream component of the RAS-MAPK pathway signaling cascade. The investigational compound has the potential to address intrinsic or acquired resistance from upstream mechanisms such as RAS, RAF and MEK. HMPL-295 is one of several investigational compounds discovered by HUTCHMED that target the RAS-MAPK pathway.
Fruquintinib:
| Title: |
| Fruquintinib plus sintilimab in advanced cervical cancer patients: Results from a multicenter, single-arm Phase II study |
| Lead Author: |
| Xiaotian Han, Oncologic Gynecology Department, Fudan University Shanghai Cancer Center, Shanghai, China |
| Type: |
| Oral presentation |
| Abstract # & Link: |
| 289MO |
| Session & Location: |
| ESMO Asia – Gynaecological cancers (ID 28), Hall 401 |
| Date & Time: |
| Friday, December 1, 2023, 11:25 am Singapore time |
| Title: |
| Fruquintinib plus sintilimab in patients with advanced non-small cell lung cancer ("NSCLC") with PD-L1 positive expression: A multicenter, single-arm phase II study |
| Lead Author: |
| Shun Lu, Shanghai Lung Cancer Center, Shanghai Chest Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China |
| Abstract # & Link: |
| 496P |
| Session & Location: |
| ESMO Asia – Poster Display (ID78), Exhibition area |
| Date & Time: |
| Saturday, December 2, 2023, 5:50 pm Singapore time |
These presentations will report results from the cervical cancer and NSCLC patient cohorts of the basket clinical trial in China of fruquintinib plus sintilimab. This trial is an open-label, multi-center, non-randomized, Phase ?? study to assess the safety and efficacy of fruquintinib in combination with sintilimab in patients with advanced cervical cancer, endometrial cancer ("EMC"), gastric cancer (GC), hepatocellular carcinoma (HCC), NSCLC or renal cell carcinoma ("RCC"). Data from the EMC and RCC cohorts of this trial led to the initiation of registration enabling programs. This combination treatment showed promising antitumor activity in advanced cervical cancer and NSCLC patients, particularly for patients with PD-L1 positive status. This combination treatment also showed manageable toxicity ...